Compare HIHO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | VRAX |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Hong Kong | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 2.9M |
| IPO Year | 1996 | 2022 |
| Metric | HIHO | VRAX |
|---|---|---|
| Price | $1.18 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 8.6K | ★ 15.3M |
| Earning Date | 01-20-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $7,080,000.00 | $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $120.89 | ★ N/A |
| Revenue Growth | ★ 3.31 | N/A |
| 52 Week Low | $1.12 | $0.35 |
| 52 Week High | $2.05 | $3.20 |
| Indicator | HIHO | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 30.09 | 45.67 |
| Support Level | $1.12 | $0.43 |
| Resistance Level | $1.28 | $0.87 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 26.44 | 16.11 |
Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).